Haizheng Pharmaceutical (600267.SH) subsidiary obtained approval document approval for veterinary drug products

Zhitongcaijing · 2d ago

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. Recently, Zhejiang Haizheng Animal Health Products Co., Ltd. (“Haizheng Animal Health Insurance Company”), a wholly-owned subsidiary of Haizheng Insurance Company, and Yunnan Biopharmaceutical Co., Ltd. (“Yunnan Biology”), a wholly-owned subsidiary of Haizheng Mobile Insurance Company, received approval documents for doxycycline hydrochloride tablets and swine fever virus E2 protein recombinant bacuvirus vaccine (WH-09 strain).

This time, Haizheng Animal Insurance Company and Yunnan Biotech have respectively obtained approval numbers for doxycycline hydrochloride tablets and swine fever virus E2 protein recombinant bacuvirus inactivated vaccine (WH-09 strain), which will further enrich the company's product line and product structure in the veterinary medicine and veterinary vaccine sector, which is conducive to further promoting the company's strategic layout in the veterinary medicine and veterinary vaccine sectors and enhancing the company's market competitiveness.